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Abstract
Leukemia inhibitory factor (LIF) is a member of the gp130
cytokine family and signals through the receptor complex
of gp130 and the LIF receptor (LIFR) to activate the
JAK/STAT signaling cascade. Since LIF activates STATs
1 and 3 in adipocytes, we examined the effects of LIF on
3T3-L1 adipocytes. Our studies clearly demonstrate that
LIF treatment had minimal effects on adipocyte differ-
entiation as judged by marker gene expression, but did
inhibit triacylglyceride (TAG) accumulation during
adipogenesis. Acute treatment with LIF resulted in
increased expression of suppressors of cytokine signaling-3
(SOCS3) and CCAAT/enhancer-binding protein-
(C/EBP) mRNA in 3T3-L1 adipocytes. Moreover, the
upregulation of C/EBP correlated with binding to three
sites in the C/EBP promoter by LIF-activated protein
complexes that contained STAT1 and not STAT3.
Chronic treatment with LIF resulted in decreased protein
levels of sterol regulatory element binding protein-1
(SREBP1) and fatty acid synthase (FAS), but had no effect
on the expression of other adipocyte marker proteins or on
TAG levels in mature 3T3-L1 adipocytes. LIF had a small
effect on insulin-stimulated glucose uptake in 3T3-L1
adipocytes, but did not cause insulin resistance following
chronic treatment. These findings indicate that LIF has
similar and distinct effects in comparison with the effects of
other gp130 cytokines on cultured fat cells. In summary,
our results support a role for LIF in the regulation of
proteins involved in lipid synthesis and in the modulation
of signal transduction pathways in 3T3-L1 adipocytes.
Journal of Endocrinology (2005) 185, 485–496
Introduction
Leukemia inhibitory factor (LIF) is a member of the
gp130 cytokine family, cytokines which are unrelated by
sequence, but are structurally similar and share a common
receptor, gp130 (Robinson et al. 1994, Kishimoto et al.
1995). LIF has pleiotropic actions which include main-
taining totipotency of embryonic stem cells (Williams et al.
1988), enhancing survival of peripheral neurons (Murphy
et al. 1991) and oligodendrocytes (Butzkueven et al. 2002),
and promoting bone formation (Dazai et al. 2000). LIF has
also been demonstrated to have multiple effects on
adipocytes and adipose tissue. Initially, LIF was character-
ized as an inducer of cachetic weight loss in mice engrafted
with a melanoma cell line that overproduces LIF (Mori
et al. 1989). Subsequently, LIF was found to inhibit
lipoprotein lipase (LPL) expression and activity in 3T3-L1
and 3T3-F442A adipocytes, without affecting the rate of
lipogenesis (Marshall et al. 1994). In addition, adipogenic
effects of LIF have been indicated by enhanced activity of
glycerol-phosphate dehydrogenase and accumulation of
lipid in Ob1771 cells during adipogenesis (Aubert et al.
1999). However, other findings have shown that
LIF prevents adipogenesis in bone marrow stromal cells
(Gimble et al. 1994) and in 3T3-L1 cells (Ohsumi et al.
1994). Thus, it is likely that the effects of LIF on
adipocytes vary with the developmental stage of the cells
or tissue.
Cytokines in the gp130 family exhibit functional
redundancy as they signal through shared receptor com-
ponents (Kishimoto et al. 1995). Ciliary neurotropic factor
(CNTF), oncostatin M, cardiotropin-1 (CT-1), and LIF
bind the LIF receptor (LIFR), in addition to the common
receptor, gp130 (Baumann et al. 1993, Wollert et al. 1996).
Oligomerization of LIFR and gp130 activates the associ-
ated JAK kinase, which phosphorylates tyrosine moieties
on the cytoplasmic tail of the receptor. The phos-
phorylated tyrosines serve as docking sites for signal
transducers and activators of transcription (STATs) 1 and
3, which then become phosphorylated, dissociate and form
dimers. The STAT dimers immediately translocate to the
nucleus to regulate expression of target genes.
Recent work in our laboratory has examined the effects
of two other gp130 cytokines, CNTF and CT-1, on
adipocytes (Zvonic et al. 2003, 2004). CNTF increased
expression and activation of insulin signaling molecules in
3T3-L1 adipocytes, but decreased expression of fatty acid
synthase (FAS) and sterol regulatory element binding
protein-1 (SREBP1). Like CNTF, CT-1 decreased
expression of FAS protein but also decreased expression of
insulin receptor substrate-1 (IRS-1) in 3T3-L1 adipocytes,
indicating both overlapping and divergent effects of gp130
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cytokines on adipocytes. To further elucidate the role of
gp130 cytokines on adipocytes, we have investigated the
action of LIF on 3T3-L1 adipocytes. As previously
observed with CT-1 and CNTF, LIF neither promoted
nor attenuated adipogenesis, in contrast to previous find-
ings for LIF (Gimble et al. 1994, Aubert et al. 1999). We
have also shown that FAS and SREBP1 protein levels
decreased after a chronic treatment with LIF. In addition,
both suppressors of cytokine signaling-3 (SOCS3) and
CCAAT/enhancer-binding protein- (C/EBP) mRNA
were rapidly induced following treatment of 3T3-L1
adipocytes with LIF. We identified three STAT1 binding
sites in the C/EBP promoter at positions 696 to
679, 780 to 763, and 1491 to 1475. Unlike
other gp130 cytokines, LIF had no effect on basal or
insulin-stimulated glucose uptake, or on the expression of
the insulin responsive glucose transporter GLUT4. In
summary, our results demonstrate novel and specific
effects of LIF on 3T3-L1 adipocytes, suggesting a role for
LIF as a regulator of lipid synthesis and an effector of signal
transduction in fat cells.
Materials and Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), fetal
bovine serum (FBS), and leukemia inhibitory factor (LIF)
were purchased from Invitrogen. Murine interferon-
(IFN) was purchased from Boehringer Mannheim.
Bovine serum and growth hormone (GH) were purchased
from Sigma. Foxo1, STAT1, STAT3, and highly
phospho-specific STAT5 (Tyr649) antibodies were pur-
chased from Upstate Biotechnology (Waltham, MA,
USA); STAT3, STAT5A, peroxisome proliferator acti-
vated receptor- (PPAR), and SREBP1 antibodies were
purchased from Santa Cruz (Santa Cruz, CA, USA);
STAT3, highly phospho-specific STAT3 (Tyr705) anti-
body and FAS antibody were purchased from BD Trans-
duction Laboratories (San Jose, CA, USA). LPL antibody
was purchased from Research Diagnostics, Inc. (Flanders,
NJ, USA), and highly phospho-specific STAT1 (Tyr701)
was purchased from Biosource (Camarillo, CA, USA).
[-32P]dCTP and [-32P]dATP were both purchased
from Perkin-Elmer (Shelton, CT, USA) and Amersham
Biosciences. Deoxynucleotide thymine triphosphate,
dATP, and dGTP were purchased from Amersham Bio-
sciences. DNase polymerase I large (Klenow) fragment
was purchased from Promega.
Cell culture
Murine 3T3-L1 preadipocytes were plated and grown to
2 days post-confluence in DMEM containing 10% bovine
serum. Medium was changed every 48 h. Cells were
induced to differentiate by changing the medium to
DMEM containing 10% FBS, 0·5 mM 3-isobutyl-
methylxanthine, 1 µM dexamethasone, and 1·7 µM insulin
(MDI). After 48 h, this medium was replaced with
DMEM supplemented with 10% FBS, and the cells
were maintained in this medium until utilized for
experimentation.
Preparation of whole cell extracts
Cell monolayers were rinsed with PBS and then harvested
in a nondenaturing buffer containing 10 mM Tris (pH
7·4), 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1%
Triton X-100, 0·5% Nonidet P-40, 1 µM phenylmethyl-
sulfonyl fluoride, 1 µM pepstatin, 50 trypsin inhibitory
milliunits of aprotinin, 10 µM leupeptin, and 2 mM
sodium vanadate. Samples were extracted for 30 min on
ice and centrifuged at 15 000 r.p.m. at 4 C for 15 min.
Supernatants containing whole cell extracts were analyzed
for protein content by BCA analysis (Pierce) according to
the manufacturer’s instructions.
Gel electrophoresis and immunoblotting
Proteins were separated in 7·5% polyacrylamide (National
Diagnostics, Atlanta, GA, USA) gels containing sodium
dodecyl sulfate (SDS) according to the method of Laemmli
(1970) and transferred to nitrocellulose (Bio-Rad) in
25 mM Tris, 192 mM glycine, and 20% methanol. Fol-
lowing transfer, the membrane was blocked in 4% milk
overnight at 4 C. Results were visualized with horse-
radish peroxidase (HRP)-conjugated secondary antibodies
(Jackson ImmunoResearch Laboratories, West Grave,
PA, USA) and enhanced chemiluminescence (Pierce
Biotechnology, Rockford, IL, USA).
Determination of 2-deoxyglucose
The assay of 2-[3H]deoxyglucose was performed as pre-
viously described (Stephens & Pekala 1991). Briefly,
mature 3T3-L1 adipocytes were serum deprived for 4 h
and then incubated in the presence or absence of insulin
(44 nM) for 10 min. Glucose uptake was initiated by
addition of 2-[3H]deoxyglucose at a concentration of
0·1 mM 2-deoxyglucose in 1 µCi 2-[3H]deoxyglucose in
Krebs-Ringer-Hepes buffer and incubated for 3 min at
room temperature. Glucose uptake is reported as [3H]
radioactivity, corrected for nonspecific diffusion (5 µM
cytochalasin B) and normalized to total protein content as
determined by BCA analysis. Uptake measurements were
performed in triplicate under conditions where hexose
uptake was linear.
RNA analysis
Total RNA was isolated from cell monolayers with Trizol
(Invitrogen) according to the manufacturer’s instructions
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with minor modifications. For Northern blot analysis,
15 µg total RNA were denatured in formamide and
electrophoresed through a formaldehyde/agarose gel. The
RNA was transferred to Zeta Probe-GT (Bio-Rad),
cross-linked, hybridized, and washed as previously
described (Stephens & Pekala 1992). Strippable probes
were labeled by random priming using the Klenow
fragment and [-32P]dATP using Strip-EZ DNA
(Ambion, Austin, TX, USA) according to manufacturer’s
instructions.
Electrophoretic mobility shift analysis (EMSA)
Double-stranded oligonucleotides were annealed by heat-
ing single-stranded 5 and 3 oligonucleotides in a boiling
water bath and gradually cooling to room temperature.
The 4 µg of double-stranded oligonucleotides were 5-end
labeled with 20 µCi [32P] (400–800 Ci/mmol) dCTP and
with 1 µl each of 5 mM dATP, dTTP, and dGTP with
Klenow fragment. The end-labeling reaction was incu-
bated for 15 min at 30 C and was stopped by adding 1 µl
0·5 M EDTA. End-labeled oligonucleotides were purified
using a Microspin G-25 column, according to the manu-
facturer’s instructions (Amersham Biosciences). Specific
activity of the oligonucleotides was determined by scintil-
lation counting. Nuclear extracts were incubated with
the end-labeled oligonucleotides (50 000 c.p.m./µl) for
30 min on ice. The samples were loaded into a pre-run
(1 h, 100 V at 4 C) 6% acrylamide/bisacrylamide TBE
gel containing 90 mM Tris, 90 mM boric acid, and 2 mM
EDTA, pH 8·0. For supershift analysis, nuclear extracts
were preincubated with 4 µg antibody for 1 h at room
temperature. The gels were run at 20 mA for approxi-
mately 2 h. The gels were dried at 80 C for 1 h under a
vacuum and then exposed to Kodak BioMax MS film
with a Kodak BioMax high energy intensifying screen.
Triglyceride assay
Cell monolayers were washed with PBS, harvested in a
buffer containing 2 M NaCl, 2 mM EDTA, 50 mM
sodium phosphate, pH 7·4 and then sonicated to
homogenize the cell suspension. Ten microliters of the
lysate were mixed with 10 µl tert-butyl alcohol and 5 µl of
a Triton X-100/methyl alcohol mixture (1:1 vol/vol), and
were then assayed for triglyceride content using a serum
triglyceride determination kit according to the manufac-
turer’s instructions (Sigma). Triglyceride levels were
normalized to protein content by BCA (Pierce). Each
treatment condition was performed in triplicate and each
sample was analyzed twice.
Statistical analysis
The statistical analyses of the data were performed using
ANOVA and the post hoc Scheffé F-test.
Results
To determine if LIF treatment could modulate adipogen-
esis, 3T3-L1 preadipocytes were induced to differentiate
in the presence or absence of exogenously added LIF. The
cells were exposed to LIF (0·5 nM) for the entire course of
differentiation with a fresh bolus of LIF added at the time
of induction and every 24 h after that. Whole cell extracts
were harvested at the time points indicated in Fig. 1 and
were analyzed by Western blotting. Adipogenesis was
assessed by induction of PPAR, C/EBP, fatty acid
transport protein-4 (FATP4), STAT5A, FAS and adipo-
nectin proteins. Although LIF attenuated the induction of
PPAR, C/EBP, and FAS at 48 h and/or 72 h, LIF did
not affect the overall expression of these markers of
adipogenesis at 120 h. The induction in STAT5A expres-
sion was unaffected by the presence of LIF. The induction
of adiponectin was decreased at 96 h, but present at similar
levels at 120 h. The expression of STAT3 does not change
during adipogenesis (Stewart et al. 1999) and is shown as a
loading control (Fig. 1). Phosphorylation of STAT3 was
detected in preadipocytes following 15 min stimulation
with LIF. A longer exposure of the film detected a low
level of STAT3 phosphorylation through the course of
differentiation.
Since LIF is a potent activator of STATs 1 and 3 in
3T3-L1 cells (Stephens et al. 1998) we examined the
action of LIF on mature adipocytes. Whole cells extracts
were collected from fully differentiated 3T3-L1 adipocytes
that were treated with LIF for the various times indicated
in Fig. 2. Although the phosphorylation of STATs 1 and 3
was detected at 15 and 45 min of stimulation, there were
no changes in the level of PPAR, Foxo1, SREBP1, FAS,
or acetyl CoA carboxylase (ACC) proteins during the time
course (Fig. 2). Therefore, we investigated the effect of a
chronic LIF treatment on 3T3-L1 adipocytes. Fully dif-
ferentiated adipocytes were stimulated with LIF for the
times indicated in Fig. 3, with a fresh bolus of LIF added
every 24 h. Chronic LIF treatment resulted in decreased
protein levels of FAS and SREBP1 at 120 h, but the levels
for Foxo1, PPAR, LPL and ACC were unchanged.
Efficacy of LIF treatment is shown by the phosphorylation
of STAT3 during the time course, and positive controls for
activation of STATs 1, 3 and 5 are shown with extracts
from 3T3-L1 adipocytes stimulated for 15 min with IFN,
LIF and GH respectively.
Since other gp130 cytokines have been reported to have
effects on insulin signaling and glucose uptake, we inves-
tigated the ability of LIF to regulate glucose uptake in
3T3-L1 adipocytes. As shown in Fig. 4A, mature 3T3-L1
adipocytes were pretreated with LIF for 30 min, 48 h or
96 h. Adipocytes were stimulated with insulin for 15 min
and assayed for uptake of 2-[3H]deoxyglucose. As shown
in Fig. 4A, insulin treatment induced an approximately
fourfold increase in glucose uptake for all time points
(ANOVA F (7,16)=123·37, P=1·02E-12; Scheffé’s test).
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We observed no significant effects of LIF on the levels of
insulin-stimulated glucose uptake. Moreover, LIF had no
effects on basal glucose uptake. We also examined the
effects of LIF on glucose uptake over an acute time course
of treatment, as shown in Fig. 4B. We observed an
approximately fourfold increase in glucose uptake for all
time points (ANOVA F (9,19)=59·72, P=4·93E-12;
Scheffé’s test). Exposure to LIF for 1 or 4 h had no effect
on insulin-stimulated glucose uptake; however, at 2 h,
there was a consistently observed decrease in insulin-
stimulated glucose uptake, but this was not statistically
significant, as shown in Fig. 4B. We observed no signifi-
cant effects of LIF on basal glucose uptake (Fig. 4B).
Furthermore, there were no effects on the level of GLUT4
mRNA over a time course of 24 h (Fig. 5). We also
examined the effects of a 2-h pretreatment with CT-1 on
glucose uptake. Basal or insulin-stimulated levels of glu-
cose uptake were not significantly different from control
levels (Fig. 4B).
To examine the effects of LIF on the regulation of
mRNA for several adipocyte genes, total RNA was
collected from fully differentiated 3T3-L1 adipocytes fol-
lowing treatment with LIF for the times indicated in
Fig. 5. Although no changes were detected for C/EBP,
C/EBP, or aP2, LIF induced a rapid and transient
upregulation of mRNA for SOCS3 and C/EBP within
one hour of stimulation. Furthermore, the upregulation of
SOCS3 and C/EBP was independent of ERK/MAP
kinase activity, as pretreatment with the MEK inhibitor,
U0126, did not block the induction by LIF (data not
shown). Induction of SOCS3 by gp130 cytokines has
been demonstrated in adipocytes (Zvonic et al. 2004) and
is well characterized in other cell types (Krebs & Hilton
2001).
The role of STAT3 in the upregulation of C/EBP has
been investigated in other cell types, and evidence indi-
cated that the 115 to 98 site in the C/EBP
promoter was bound by STAT3 following stimulation
with interleukin (IL)-6 (Yamada et al. 1997, Hutt et al.
2000). Hence, we examined the ability of LIF to induce
binding to the 115 to 98 element of the C/EBP
promoter. Electromobility shift assay was performed with
nuclear extracts from 3T3-L1 adipocytes treated with LIF
for 15 min. As shown in Fig. 6, no detectable binding to
the 115 to 98 oligonucleotide was observed with LIF
treatment, indicating that this site does not contribute to
the regulation of C/EBP by LIF in 3T3-L1 adipocytes.
Thus, we looked for other possible STAT binding sites in
Figure 1 LIF attenuates the differentiation of 3T3-L1 adipocytes. Whole cell extracts were
prepared from 3T3-L1 preadipocytes or 3T3-L1 cells induced to differentiate in the
presence (+) or absence () of LIF (0·5 nM). Media samples were also collected for
detection of adiponectin. Cells were treated every 24 h with a fresh bolus of LIF.
Seventy-five micrograms of each sample were separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis. The detection system was
HRP-conjugated secondary antibodies and enhanced chemiluminescence. This is a
representative experiment independently performed three times.
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the C/EBP promoter and identified four sites at positions
616 to 599, 696 to 679, 780 to 763, and
1491 to 1475 that resembled the consensus STAT
recognition sequence TTCNNNGAA (Table 1). Free (on
Fig. 6) indicates the presence of the probe alone with no
added protein extract to the sample. As shown in Fig. 6,
LIF-induced nuclear protein complexes shifted the sites at
696 to 679, 780 to 763, and 1491 to
1475, but not the 616 to 599 oligonucleotide
(data not shown). Cold competition analysis with excess
unlabeled oligonucleotides revealed the specificity of these
interactions (data not shown). Because LIF is a strong
activator of STAT3 (see Figs 2 and 3), we hypothesized
that the protein complex contained STAT3. However,
supershift analysis using multiple STAT3 antibodies, along
with antibodies against STAT1 and STAT5A clearly
indicates that the protein complex induced by LIF pri-
marily contains STAT1 (Fig. 7A, panels 1–3, lane 7). As
shown in Fig. 7A, no supershift was detected with a
STAT5A antibody (lane 8) or with STAT3 antibodies that
recognize the carboxy terminus (lane 4), amino acids
1–175 (lane 5), or amino acids 688–722 (lane 6) of
STAT3. We also examined the induction of binding by
LIF-induced proteins to two oligonucleotides that are
routinely used as positive controls for STAT3 binding, the
168 to 148 site from the rat 2-macroglobulin (2M)
promoter (Hattori et al. 1990) and the m67 oligonucleotide
derived from the c-fos 345 to 323 promoter, which
strongly binds cytokine-induced protein complexes
(Wagner et al. 1990). As shown in Fig. 7A, LIF treatment
induced binding to these oligonucleotides (panels 4 and 5,
lane 3). Similar to our findings with the C/EBP pro-
moter sites, only STAT1 antibody supershifted the protein
complex induced by LIF for both the m67 and 2M
oligonucleotides. To further investigate the activation of
STAT3 binding by LIF, we used a longer m67 oligo-
nucleotide for EMSA analysis (Fig. 7B). We detected
binding by two protein complexes that were induced by
LIF. The weak binding by the protein complex exhibiting
slower mobility was blocked by antibodies for STAT3
(lanes 4 and 5). The more prominent protein complex
exhibiting faster mobility was supershifted by STAT1
Figure 2 Acute LIF treatment did not affect expression of adipocyte marker proteins in
mature 3T3-L1 adipocytes. Fully differentiated 3T3-L1 adipocytes were treated with LIF
(0·5 nM) for the times indicated. Seventy-five micrograms protein from whole cell extracts
were loaded into the gel for each sample. The samples were subjected to SDS-PAGE, and
then were transferred to nitrocellulose for immunoblot analysis. This is a representative
experiment independently performed two times.
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antibody (lane 6). STAT5A antibody was included as a
negative control. Thus, although LIF is a potent activator
of STAT3, STAT1 appears to preferentially bind under
these conditions in 3T3-L1 adipocytes. Furthermore, our
supershift analysis suggests that STAT1 contributes to the
LIF-induced modulation of C/EBP in adipocytes.
Since we observed a delay in the expression of several
adipocyte marker proteins during adipogenesis in the
presence of LIF, we examined the effect of LIF on the
accumulation of triglycerides (TAG) during the differ-
entiation of 3T3-L1 cells. 3T3-L1 preadipocytes were
induced to differentiate in the presence or absence of LIF
(0·5 nM). A fresh bolus of LIF was added every 24 h. Cells
were harvested at the times indicated in Fig. 8A. As shown
in Fig. 8A, in the absence of LIF treatment, triglyceride
content increased during differentiation (ANOVA F
(7,16)=28·51, P=6·88E-8; Scheffé’s test). Although the
triglyceride content also increased in the LIF-treated cells
during adipogenesis, the level of triglycerides in LIF-
treated cells at 120 h was significantly lower than the level
observed in the untreated adipocytes (Fig. 8A). We also
examined the effect of LIF on triglyceride content in
mature adipocytes. Mature 3T3-L1 adipocytes were
stimulated with LIF for the various times indicated in
Fig. 8B. As shown in Fig. 8B, LIF treatment did not
diminish the level of triglyceride in 3T3-L1 adipocytes
(ANOVA F (5,6)=0·30, P=0·89).
Discussion
Recent work from our laboratory has demonstrated that
gp130 cytokines, CT-1 and CNTF, have overlapping and
divergent effects on the expression and activation of
proteins of lipid and glucose metabolism in adipocytes
(Zvonic et al. 2003, 2004). The gp130 cytokines activate
the JAK/STAT pathway via the gp130 and LIF receptors.
Because LIF also signals through gp130 and LIFR, we
hypothesized that LIF would regulate adipocyte proteins.
Our studies with 3T3-L1 cells have shown that LIF
activates STATs 1 and 3 in preadipocytes and mature
adipocytes. Because LIFR is expressed more abundantly in
preadipocytes (Zvonic et al. 2003), we predicted that LIF
would regulate adipogenesis as was previously shown in
3T3-L1 cells (Ohsumi et al. 1994). However, we observed
only modest effects of LIF on the in vitro differentiation of
3T3-L1 adipocytes. In another cell line, Ob1771, LIF
promotes differentiation (Aubert et al. 1999). Thus, it is
possible that this discrepancy is due to differences in
commitment to the adipocyte lineage of these two cell
lines.
Since adipocytes are responsive to LIF, we studied the
effects of this cytokine on fully differentiated adipocytes.
Acute treatment did not regulate the expression of several
adipocyte proteins, but expression of SOCS3 and C/EBP
mRNA was strongly and transiently stimulated by LIF.
SOCS3 is a member of the SOCS protein family, which is
characterized by the ability to negatively modulate
cytokine signaling (Krebs & Hilton 2001). The induction
of SOCS3 expression has been demonstrated by many
cytokines, and direct regulation by STAT proteins has
been described (Auernhammer et al. 1999). These data are
consistent with recent findings from our laboratory that
CNTF and CT-1 upregulate SOCS3 mRNA (Zvonic
et al. 2004). Interestingly, there is recent evidence that
SOCS3 is a regulator of insulin signaling and may cause
insulin resistance in adipocytes through its effects on IRS
protein expression (Shi et al. 2004). Although we did not
observe any significant effects on insulin-stimulated glu-
cose uptake by LIF, the upregulation of SOCS3 by gp130
cytokines is clearly a major component of JAK/STAT
signaling in adipocytes.
Figure 3 The effect of chronic treatment of LIF on 3T3-L1
adipocytes. Whole cell extracts were prepared from fully
differentiated 3T3-L1 adipocytes following treatment with LIF
(0·5 nM) for the indicated times. Cells were treated every 24 h
with a fresh bolus of LIF. Seventy-five micrograms of each sample
were separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis. (+) indicates a positive control
of a 15-min treatment with IFN, LIF and GH for activation of
STAT1, STAT3 and STAT5 respectively. This is a representative
experiment independently performed two times.
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C/EBP is a basic-leucine zipper transcription factor
with a well-established role in adipogenesis (Darlington
et al. 1998), although knock-out studies indicate that
C/EBP alone is weakly adipogenic (Tanaka et al. 1997).
The IL-6 upregulation of C/EBP in mammary epi-
thelium (Hutt et al. 2000) and HepG2 cells (Yamada et al.
1997) has been shown to be mediated by the 115 to
98 region of the promoter, but our data indicated that
this site was not sensitive to LIF regulation in adipocytes
(Fig. 6). However, three other sites at positions 696 to
679, 780 to 763, and 1491 to 1475 were
bound by LIF-activated protein complexes which con-
tained STAT1 (Fig. 6). Interestingly, the protein complex
did not contain STAT3, as we had predicted, since LIF is
a more potent activator of STAT3 than of STAT1, as
shown in Fig. 2. Moreover, we did not observe STAT3
binding to two oligonucleotides routinely used as positive
controls for STAT3 binding, the 168 to 148 site of
the rat 2M promoter (Hattori et al. 1990) and m67
(Wagner et al. 1990). Yet, our supershift analysis revealed
that these oligonucleotides were shifted by protein com-
plexes which contained STAT1. Only when we used a
long form of the m67 oligonucleotide did we detect a
faint band that represented a STAT3 binding site. Our
Figure 4 LIF does not affect insulin stimulation of glucose uptake. (A) Fully differentiated
3T3-L1 adipocytes were treated with LIF (0·5 nM) for the times indicated. Cells were
treated every 24 h with a fresh bolus of LIF. Cells were serum deprived for 4 h and then
stimulated with insulin (44 nM) for 15 min. Glucose uptake was initiated by addition of
2-[3H]deoxyglucose. Glucose uptake for each time point was measured in triplicate
and is given as the meanS.D (P<0·01; Scheffé’s test; ANOVA F (7,16)=123·37,
P=1·02E-12). (B) Fully differentiated 3T3-L1 adipocytes were serum deprived for
4 h and were stimulated with LIF (0·5 nM) for the times indicated. Cells were then
stimulated with insulin (44 nM) for 15 min. Glucose uptake was initiated by addition of
2-[3H]deoxyglucose. Glucose uptake for each time point was measured in triplicate and is
given as the meanS.D. (P<0·01; Scheffé’s test; ANOVA F (9,19)=59·72, P=4·93E-12).
This is a representative experiment independently performed two times. CTL, control
untreated cells. In both (A) and (B) the only significant differences were between basal
and insulin-stimulated conditions.
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observations strongly suggest that STAT1 preferentially
binds under these conditions in 3T3-L1 adipocytes. These
results have led us to hypothesize that the three sites in the
C/EBP promoter confer the LIF response and that
binding by STAT1 may mediate the upregulation of
C/EBP in adipocytes.
The consequences of increased expression of C/EBP
in mature adipocytes are not known. It has been shown
Figure 5 LIF induces the expression of C/EBP and SOCS3 mRNA. Total RNA was isolated
from 3T3-L1 adipocytes following treatment with LIF (0·5 nM) for the times indicated
above. Untreated cells (CTL) were harvested at the start and end of the time course.
Fifteen micrograms total RNA were electrophoresed, transferred to nylon, and subjected to
Northern blot analysis with radiolabeled probes for the indicated genes. Hybridization to
-actin is included as a loading control. This is a representative experiment independently
performed two times.
Figure 6 LIF activates binding by protein complexes from the nuclei of 3T3-L1 adipocytes
to three sites of the C/EBP promoter. Nuclear extracts were prepared from differentiated
3T3-L1 adipocytes that were untreated () or treated (+) with LIF for 15 min. For each
sample, 10 g protein were incubated with 50 000 c.p.m./ml of the indicated 32P-labeled
probe of the C/EBP promoter. Free indicates the presence of the probe alone with no
added protein extract to the sample. The protein–DNA complexes were resolved by
electromobility shift assay. This is a representative experiment independently performed
two times. Nuc, nucleus; Cyto, cytosol.
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that tumor necrosis factor- (Kurebayashi et al. 2001),
dexamethasone (MacDougald et al. 1994), and insulin
(MacDougald et al. 1995) also upregulate C/EBP in
mature adipocytes in a rapid and transient manner. Inter-
estingly, the lack of effect of LIF on C/EBP expression
suggests that although C/EBP is regulated by C/EBP in
differentiating adipocytes (Lane et al. 1999), it is not
affected by C/EBP expression in mature adipocytes. In
other cell types, C/EBP negatively regulates the expres-
sion of the 2 chain of type I collagen, a critical structural
component of the extracellular matrix (Greenwel et al.
2000). C/EBP upregulates expression of IL-6 in astro-
cytes (Schwaninger et al. 2000), intestinal epithelial cells
(Hungness et al. 2002), and osteoblasts (Ruddy et al.
2004); thus, IL-6, an adipokine associated with obesity
(Bastard et al. 2000) may be a transcriptional target of
C/EBP in adipocytes as well. Effects on C/EBP targets
would likely be transient, since the induction of C/EBP
is short-lived (MacDougald et al. 1994). These potential
outcomes of increased C/EBP expression give insight
into one means by which LIF exerts effects on adipocyte
function.
We also examined the effect of a chronic administration
of LIF in fully differentiated adipocytes. Both FAS and
SREBP1 proteins exhibited decreased expression after
120 h of LIF stimulation. FAS is the enzyme catalyzing all
of the steps in the synthesis of palmitate from acetyl CoA
and malonyl, and the level of its expression is coupled to
the rate of lipogenesis (Sul & Wang 1998). SREBP1 is a
transcription factor known to modulate genes associated
with fat and cholesterol metabolism (Horton et al. 2002),
including FAS (Bennett et al. 1995). The decreased
expression of SREBP1 and FAS may result in changes in
lipid accumulation in adipocytes as a result of prolonged
exposure to LIF. Indeed, LIF decreases TAG accumula-
tion during adipogenesis, but has little effect on TAG
levels in fully differentiated cells. However since the
effects on SREBP and FAS require chronic treatment
(5 days), it is highly likely that these effects are indirect.
In the light of recent studies demonstrating upregulation
of GLUT4 expression by CNTF (Zvonic et al. 2003) and
improved insulin-stimulated glucose uptake by CT-1
(Zvonic et al. 2004), we investigated the ability of LIF to
Table 1 Potential STAT binding sites in the C/EBP promoter
Sequence LIF-responsive
Position
115 to 98 TCG TTC CCA GCA GCA AC No
696 to 679 AAT TTC AGA ATA ATA TCC Yes
780 to 763 CTT TTC ACG AAT TTT GAA Yes
1491 to 1475 AT TTC TGG AAA AAT TGA A Yes
168 to 148 2M TCC TTC TGG GAA TC Yes
m67 CGT TTC CCG TAA ATC CCT CCC Yes
Consensus TTC NNN GAA
Figure 7 Binding of LIF-activated STAT1, not STAT3, to sites in the
C/EBP promoter. Nuclear extracts were prepared from fully
differentiated 3T3-L1 adipocytes that were untreated () or
treated with LIF for 15 min. In the top panel of gels (A), the
untreated () sample is present in lane 2 and the LIF treated
samples are present in lanes 3–8. In the m67 gel (B), all the
samples are LIF treated except the one labeled (). For each
sample, 10 g protein were incubated with 50 000 c.p.m./ml of
the 32P-labeled probe of the C/EBP promoter or of the STAT3
oligonucleotides for m67 or the 168 to 148 site of the rat
2M promoter. For supershift, samples were preincubated with the
indicated antibodies (4 g): STAT3 1 (Santa Cruz C-20), 2 (BD
Transduction Laboratories), 3 (Upstate Biotechnology), STAT1
(Upstate Biotechnology), and STAT5 (Santa Cruz L-20). The
protein–DNA complexes were resolved by electromobility shift
assay. Free indicates the presence of the probe alone with no
added protein extract to the sample. This is a representative
experiment independently performed two times.
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modulate glucose uptake in adipocytes. Our findings
demonstrate that LIF does not substantially affect basal or
insulin-stimulated glucose uptake, and does not modulate
expression of GLUT4. Thus, LIF likely does not greatly
affect glucose disposal in adipose tissue.
In summary, we have demonstrated that LIF activates
the JAK/STAT pathway in 3T3-L1 preadipocytes
and adipocytes. Although LIF had modest affects on
adipogenesis of 3T3-L1 cells as judged by examining
numerous fat markers, the presence of LIF during differ-
entiation resulted in a significant decrease in TAG levels.
We also demonstrated that LIF increased C/EBP expres-
sion after an acute exposure. We have identified three
LIF-responsive sites in the C/EBP promoter that are
distinct from the previously reported STAT3 binding site
for IL-6 regulation in mammary epithelial cells (Hutt et al.
2000) and hepatocytes (Yamada et al. 1997). Moreover,
these three newly identified and LIF-responsive sites bind
STAT1, rather than STAT3. LIF, similar to CT-1 and
CNTF, regulated proteins involved in lipid accumulation,
SREBP1 and FAS, which may be indicative of a redun-
dant role of gp130 cytokines in the modulation of
adipocyte function. However, unlike these cytokines, LIF
had no effect on basal or insulin-stimulated glucose
uptake. These results were somewhat unexpected,
given that all three cytokines signal through the same
receptor components. Yet each cytokine activates a unique
pattern of STATs in adipocytes. CNTF only activates
STAT3 (Zvonic et al. 2003), whereas LIF activates STATs
1 and 3, and CT-1 activates STATs 1, 3 and 5 (Zvonic
et al. 2004). Therefore, we predict that the variation in
recruitment of these transcription factors mediates the
Figure 8 LIF diminishes the accumulation of triglycerides during adipogenesis. (A) 3T3-L1
cells were induced to differentiate in the presence or absence of LIF (0·5 nM). Cells were
treated every 24 h with a fresh bolus of LIF. Cells were harvested in 2 M NaCl, 2 mM
EDTA, 50 mM sodium phosphate, pH 7·4. Cell lysates were mixed in an equal volume of
tert-butyl alcohol and Y volume of a 1:1 mixture of Triton X-100 and methyl alcohol.
Trigylceride content was measured according to package instructions (Sigma). The
triglyceride level for each time point was measured in triplicate, normalized to protein
concentration (mg/mg) and is given as the meanS.D Asterisk indicates statistically
significant difference compared with all time points (P<0·01; Scheffé’s test; ANOVA F
(7,16)=28·51, P=6·88E-8). (B) Mature 3T3-L1 adipocytes were stimulated with LIF
(0·5 nM) for the times indicated and were treated every 24 h with a fresh bolus of LIF.
Triglyceride content was determined as described above (ANOVA F (5,6)=0·30, P=0·89).
This is a representative experiment independently performed two times.
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nonredundant downstream effects of gp130 cytokines in
3T3-L1 adipocytes. Furthermore, crosstalk with other
signaling pathways may contribute to the divergent
effects of gp130 cytokines. Current studies are underway
to investigate the crosstalk among gp130 cytokines in
adipocytes.
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